An HDAC-Targeted Imaging Probe LBH589-Cy5.5 for Tumor Detection and Therapy Evaluation

Molecular Pharmaceutics

Volumn 12, Issue 7, 2015, Pages 2469-2476

  Meng, Qingqing ^a   Liu, Zhiyi ^a   Li, Feng ^a   Ma, Jianjun ^b   Wang, He ^b   Huan, Yi ^c   Li, Zheng ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

histone deacetylases; LBH589; NIR fluorescent imaging; therapy evaluation; triple negative breast cancer

Indexed keywords

HISTONE DEACETYLASE; PANOBINOSTAT; VORINOSTAT; CARBOCYANINE; CY5.5 CYANINE DYE; FLUORESCENT DYE; HISTONE DEACETYLASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CANCER THERAPY; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; EX VIVO STUDY; FEMALE; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIAGNOSIS; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; HUMAN; METABOLISM; NEAR INFRARED SPECTROSCOPY; NUDE MOUSE; PROCEDURES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CARBOCYANINES; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENT DYES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; MICE, NUDE; SPECTROSCOPY, NEAR-INFRARED; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84936763373     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00167     Document Type: Article

References (33)

1. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 2006, 6, 38-51
2. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy Nat. Rev. Genet. 2009, 10, 32-42
3. Fritzsche, F. R.; Weichert, W.; Roske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; Scholman, K.; Denkert, C.; Dietel, M.; Kristiansen, G. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer BMC Cancer 2008, 8, 381
4. Rikimaru, T.; Taketomi, A.; Yamashita, Y.; Shirabe, K.; Hamatsu, T.; Shimada, M.; Maehara, Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma Oncology 2007, 72, 69-74
5. Weichert, W.; Roske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; Fritzsche, F. R.; Niesporek, S.; Denkert, C.; Dietel, M.; Kristiansen, G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy Br. J. Cancer 2008, 98, 604-10
6. Krusche, C. A.; Wulfing, P.; Kersting, C.; Vloet, A.; Bocker, W.; Kiesel, L.; Beier, H. M.; Alfer, J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis Breast Cancer Res. Treat. 2005, 90, 15-23
7. Lehmann, A.; Denkert, C.; Budczies, J.; Buckendahl, A. C.; Darb-Esfahani, S.; Noske, A.; Muller, B. M.; Bahra, M.; Neuhaus, P.; Dietel, M.; Kristiansen, G.; Weichert, W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo BMC Cancer 2009, 9, 395
8. Wilson, A. J.; Byun, D. S.; Popova, N.; Murray, L. B.; L'Italien, K.; Sowa, Y.; Arango, D.; Velcich, A.; Augenlicht, L. H.; Mariadason, J. M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer J. Biol. Chem. 2006, 281, 13548-58
9. Reid, A. E.; Hooker, J.; Shumay, E.; Logan, J.; Shea, C.; Kim, S. W.; Collins, S.; Xu, Y.; Volkow, N.; Fowler, J. S. Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain Nucl. Med. Biol. 2009, 36, 247-58
10. Hooker, J. M.; Kim, S. W.; Alexoff, D.; Xu, Y.; Shea, C.; Reid, A.; Volkow, N.; Fowler, J. S. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography ACS Chem. Neurosci. 2010, 1, 65-73
11. Yeh, H. H.; Tian, M.; Hinz, R.; Young, D.; Shavrin, A.; Mukhapadhyay, U.; Flores, L. G.; Balatoni, J.; Soghomonyan, S.; Jeong, H. J.; Pal, A.; Uthamanthil, R.; Jackson, J. N.; Nishii, R.; Mizuma, H.; Onoe, H.; Kagawa, S.; Higashi, T.; Fukumitsu, N.; Alauddin, M.; Tong, W.; Herholz, K.; Gelovani, J. G. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with (1)(8)F-FAHA NeuroImage 2013, 64, 630-9
12. Hendricks, J. A.; Keliher, E. J.; Marinelli, B.; Reiner, T.; Weissleder, R.; Mazitschek, R. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA) J. Med. Chem. 2011, 54, 5576-82
13. Wang, C.; Eessalu, T. E.; Barth, V. N.; Mitch, C. H.; Wagner, F. F.; Hong, Y.; Neelamegam, R.; Schroeder, F. A.; Holson, E. B.; Haggarty, S. J.; Hooker, J. M. Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain Am. J. Nucl. Med. Mol. Imaging 2013, 4, 29-38
14. Wang, C.; Schroeder, F. A.; Wey, H. Y.; Borra, R.; Wagner, F. F.; Reis, S.; Kim, S. W.; Holson, E. B.; Haggarty, S. J.; Hooker, J. M. In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs J. Med. Chem. 2014, 57, 7999-8009
15. Atadja, P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges Cancer Lett. 2009, 280, 233-41
16. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discovery 2006, 5, 769-84
17. Fortunati, N.; Catalano, M. G.; Marano, F.; Mugoni, V.; Pugliese, M.; Bosco, O.; Mainini, F.; Boccuzzi, G. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS) Breast Cancer Res. Treat. 2010, 124, 667-75
18. Tate, C. R.; Rhodes, L. V.; Segar, H. C.; Driver, J. L.; Pounder, F. N.; Burow, M. E.; Collins-Burow, B. M. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat Breast Cancer Res. 2012, 14, R79
19. San-Miguel, J. F.; Hungria, V. T.; Yoon, S. S.; Beksac, M.; Dimopoulos, M. A.; Elghandour, A.; Jedrzejczak, W. W.; Gunther, A.; Nakorn, T. N.; Siritanaratkul, N.; Corradini, P.; Chuncharunee, S.; Lee, J. J.; Schlossman, R. L.; Shelekhova, T.; Yong, K.; Tan, D.; Numbenjapon, T.; Cavenagh, J. D.; Hou, J.; LeBlanc, R.; Nahi, H.; Qiu, L.; Salwender, H.; Pulini, S.; Moreau, P.; Warzocha, K.; White, D.; Blade, J.; Chen, W.; de la Rubia, J.; Gimsing, P.; Lonial, S.; Kaufman, J. L.; Ocio, E. M.; Veskovski, L.; Sohn, S. K.; Wang, M. C.; Lee, J. H.; Einsele, H.; Sopala, M.; Corrado, C.; Bengoudifa, B. R.; Binlich, F.; Richardson, P. G. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Lancet Oncol. 2014, 15, 1195-206
20. Fukutomi, A.; Hatake, K.; Matsui, K.; Sakajiri, S.; Hirashima, T.; Tanii, H.; Kobayashi, K.; Yamamoto, N. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors Invest. New Drugs 2012, 30, 1096-106
21. Drappatz, J.; Lee, E. Q.; Hammond, S.; Grimm, S. A.; Norden, A. D.; Beroukhim, R.; Gerard, M.; Schiff, D.; Chi, A. S.; Batchelor, T. T.; Doherty, L. M.; Ciampa, A. S.; Lafrankie, D. C.; Ruland, S.; Snodgrass, S. M.; Raizer, J. J.; Wen, P. Y. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma J. Neurooncol. 2012, 107, 133-8
22. Lemoine, M.; Younes, A. Histone deacetylase inhibitors in the treatment of lymphoma Discovery Med. 2010, 10, 462-70
23. Xia, C.; Leon-Ferre, R.; Laux, D.; Deutsch, J.; Smith, B. J.; Frees, M.; Milhem, M. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (Temozolomide) Cancer Chemother. Pharmacol. 2014, 74, 691-7
24. Chen, K.; Chen, X. Design and development of molecular imaging probes Curr. Top. Med. Chem. 2010, 10, 1227-36
25. Luker, G. D.; Luker, K. E. Optical imaging: current applications and future directions J. Nucl. Med. 2008, 49, 1-4
26. Liu, Z.; Li, Z. Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs) Theranostics 2014, 4, 990-1001
27. Kosaka, N.; Ogawa, M.; Choyke, P. L.; Kobayashi, H. Clinical implications of near-infrared fluorescence imaging in cancer Future Oncol. 2009, 5, 1501-11
28. Luo, S.; Zhang, E.; Su, Y.; Cheng, T.; Shi, C. A review of NIR dyes in cancer targeting and imaging Biomaterials 2011, 32, 7127-38
29. Millard, C. J.; Watson, P. J.; Celardo, I.; Gordiyenko, Y.; Cowley, S. M.; Robinson, C. V.; Fairall, L.; Schwabe, J. W. Class I HDACs share a common mechanism of regulation by inositol phosphates Mol. Cell 2013, 51, 57-67
30. Sekar, T. V.; Dhanabalan, A.; Paulmurugan, R. Imaging cellular receptors in breast cancers: an overview Curr. Pharm. Biotechnol. 2011, 12, 508-27
31. Shultz, M. D.; Cao, X.; Chen, C. H.; Cho, Y. S.; Davis, N. R.; Eckman, J.; Fan, J.; Fekete, A.; Firestone, B.; Flynn, J.; Green, J.; Growney, J. D.; Holmqvist, M.; Hsu, M.; Jansson, D.; Jiang, L.; Kwon, P.; Liu, G.; Lombardo, F.; Lu, Q.; Majumdar, D.; Meta, C.; Perez, L.; Pu, M.; Ramsey, T.; Remiszewski, S.; Skolnik, S.; Traebert, M.; Urban, L.; Uttamsingh, V.; Wang, P.; Whitebread, S.; Whitehead, L.; Yan-Neale, Y.; Yao, Y. M.; Zhou, L.; Atadja, P. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors J. Med. Chem. 2011, 54, 4752-72
32. Meng, Q.; Li, F.; Jiang, S.; Li, Z. Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases ACS Med. Chem. Lett. 2013, 4, 858-62
33. Dent, R.; Trudeau, M.; Pritchard, K. I.; Hanna, W. M.; Kahn, H. K.; Sawka, C. A.; Lickley, L. A.; Rawlinson, E.; Sun, P.; Narod, S. A. Triple-negative breast cancer: clinical features and patterns of recurrence Clin. Cancer Res. 2007, 13, 4429-34